Prognostic impact of high p16/cyclin D1 index in breast cancer

被引：1

作者：

Kim, Gi Jeong ^{[1
,2
]}

Kim, Dong-Hoon ^{[3
]}

Min, Kyueng-Whan ^{[4
]}

Kim, Se Hoon ^{[5
]}

机构：

[1] Gachon Univ, Gil Med Ctr, Dept Pathol, Coll Med, Incheon, South Korea

[2] Yonsei Univ, Dept Med, Grad Sch, Seoul, South Korea

[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Pathol, Sch Med, 29 Saemunanro, Seoul 03181, South Korea

[4] Hanyang Univ, Guri Hosp, Dept Pathol, Coll Med, Guri, Gyeonggi Do, South Korea

[5] Yonsei Univ, Severance Hosp, Dept Pathol, Coll Med, Seoul, South Korea

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2019年 / 12卷 / 06期

关键词：

Breast cancer; p16; cyclin D1; index; prognosis; CYCLIN D1; RETINOBLASTOMA PROTEIN; P16; PROTEINS; EXPRESSION; OVEREXPRESSION; CARCINOMA; METHYLATION; RB; PROGRESSION; P16(INK4A);

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Proteins p16 and cyclin D1 (CCND1) are known to tightly regulate the G1/S transition during the cell cycle, but their role in breast cancer development and progression is not clear. We investigated 224 cases of breast cancer from the Kangbuk Samsung Medical Center between 2000-2005. Expression levels of p16 and CCND1 were assessed by tissue microarray-based immunohistochemistry. A p16/CCND1 index was divided into low- and high-expression groups using receiver operating characteristic curves. The p16/CCND1 index was significantly different across molecular subtypes and a high p16/CCND1 index was statistically correlated with survival rates. This p16/CCND1 index may be an indicator of poor patient outcome and thus, represents a potential therapeutic target.

引用

页码：2224 / 2232

页数：9

共 42 条

[1] Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer [J].

Aaltonen, Kirsimari ;

Amini, Rose-Marie ;

Landberg, Goran ;

Eerola, Hannaleena ;

Aittomaki, Kristiina ;

Heikkila, Paivi ;

Nevanlinna, Heli ;

Blomqvist, Carl .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (01) :75-82

[2] Promoter methylation and expression changes of CDH1 and P16 genes in invasive breast cancer and adjacent normal breast tissue [J].

Cavusoglu, A. Celebiler ;

Sevinc, A. I. ;

Saydam, S. ;

Canda, T. ;

Baskan, Z. ;

Kilic, Y. ;

Sakizli, M. .

NEOPLASMA, 2010, 57 (05) :465-472

[3] p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells [J].

Cen, Ling ;

Carlson, Brett L. ;

Schroeder, Mark A. ;

Ostrem, Jamie L. ;

Kitange, Gaspar J. ;

Mladek, Ann C. ;

Fink, Stephanie R. ;

Decker, Paul A. ;

Wu, Wenting ;

Kim, Jung-Sik ;

Waldman, Todd ;

Jenkins, Robert B. ;

Sarkaria, Jann N. .

NEURO-ONCOLOGY, 2012, 14 (07) :870-881

[4] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].

Cheang, Maggie C. U. ;

Chia, Stephen K. ;

Voduc, David ;

Gao, Dongxia ;

Leung, Samuel ;

Snider, Jacqueline ;

Watson, Mark ;

Davies, Sherri ;

Bernard, Philip S. ;

Parker, Joel S. ;

Perou, Charles M. ;

Ellis, Matthew J. ;

Nielsen, Torsten O. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750

[5] C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition [J].

Cho, Tae-Min ;

Kim, Ji Young ;

Kim, Yoon-Jae ;

Sung, Daeil ;

Oh, Eunhye ;

Jang, Seojin ;

Farrand, Lee ;

Van-Hai Hoang ;

Cong-Truong Nguyen ;

Ann, Jihyae ;

Lee, Jeewoo ;

Seo, Jae Hong .

CANCER LETTERS, 2019, 447 :141-153

[6] High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance) [J].

Chumsri, Saranya ;

Sperinde, Jeff ;

Liu, Heshan ;

Gligorov, Joseph ;

Spano, Jean-Philippe ;

Antoine, Martine ;

Aspitia, Alvaro Moreno ;

Tan, Winston ;

Winslow, John ;

Petropoulos, Christos J. ;

Chenna, Ahmed ;

Bates, Michael ;

Weidler, Jodi Marie ;

Huang, Weidong ;

Dueck, Amylou ;

Perez, Edith A. .

CLINICAL CANCER RESEARCH, 2018, 24 (13) :3053-3058

[7]

Dublin EA, 1998, INT J CANCER, V79, P71, DOI 10.1002/(SICI)1097-0215(19980220)79:1<71::AID-IJC14>3.0.CO

[8]

2-K

[9] The risk factor of gallbladder cancer: Hyperplasia of mucous epithelium caused by gallstones associates with p16/CyclinD1/CDK4 pathway [J].

Feng, Zhiqiang ;

Chen, Jinglong ;

Wei, Honglian ;

Gao, Ping ;

Shi, Jingsen ;

Zhang, Jinqian ;

Zhao, Fenglin .

EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2011, 91 (02) :569-577

[10]

Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989

← 1 2 3 4 5 →